Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590281 | 0.92 | KCNH2 (0.55) | MAP2K1KCNH2MAP2K2MAPK1MAP2K5 | |
| SCHEMBL1977165 | 0.88 | KCNH2 (0.59) | MAP2K1KCNH2MAP2K2MAP2K5CYP2C9 | |
| SCHEMBL1977779 | 0.87 | MAP2K1 (0.66) | MAP2K1KCNH2MAP2K2BRAFMAPK1 | |
| SCHEMBL9101063 | 0.87 | MAP2K1 (0.43) | MAP2K1KCNH2MAP2K2BRAFMAPK1 | |
| SCHEMBL9885440 | 0.87 | KCNH2 (0.53) | MAP2K1KCNH2MAP2K2MAP2K5CYP2C9 | |
| SCHEMBL12589905 | 0.85 | MAP2K1 (0.49) | MAP2K1KCNH2MAP2K2BRAFMAPK1 | |
| SCHEMBL1976121 | 0.84 | KCNH2 (0.47) | MAP2K1KCNH2MAP2K2MAP2K5CYP2C9 | |
| SCHEMBL9885456 | 0.82 | KCNH2 (0.46) | MAP2K1KCNH2MAP2K2MAP2K5CYP2C9 | |
| SCHEMBL1977219 | 0.81 | MAP2K2 (0.41) | MAP2K1KCNH2MAP2K2MAPK1CYP2C9 | |
| SCHEMBL1980901 | 0.80 | MAP2K1 (0.43) | MAP2K1KCNH2MAP2K2MAPK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486963-B2 | Azaindolizines and methods of use | GENENTECH, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110142826-A1 | AZAINDOLIZINES AND METHODS OF USE | GENENTECH, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110142826-A1 | AZAINDOLIZINES AND METHODS OF USE | GENENTECH, INC. | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142826-A1 | AZAINDOLIZINES AND METHODS OF USE | IKZF3, MKI67, CDKN1A | MAP2K1 19/4885KCNH2 2385/4885MAP2K2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.